{"id":"placebo-tadalafil","safety":{"commonSideEffects":[{"rate":"11-16%","effect":"Headache"},{"rate":"6-10%","effect":"Back pain"},{"rate":"5-9%","effect":"Muscle pain"},{"rate":"4-8%","effect":"Nausea"},{"rate":"3-7%","effect":"Flushing"}]},"_chembl":{"chemblId":"CHEMBL779","moleculeType":"Small molecule","molecularWeight":"389.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PDE5 inhibitors like tadalafil block the action of phosphodiesterase type 5, an enzyme that breaks down cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. This leads to increased levels of cGMP, causing smooth muscle relaxation and increased blood flow to the penis, resulting in an erection. Tadalafil is a potent and selective inhibitor of PDE5, with a long half-life that allows for once-daily dosing.","oneSentence":"Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, which works by increasing blood flow to the penis to treat erectile dysfunction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:34.295Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Erectile dysfunction"}]},"trialDetails":[{"nctId":"NCT07466030","phase":"PHASE1","title":"Tadalafil 5 mg on Storage Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of the Prostate","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"BPH (Benign Prostatic Hyperplasia)","enrollment":40},{"nctId":"NCT07447518","phase":"EARLY_PHASE1","title":"Double j Stent Related Symptoms","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-09-22","conditions":"Lower Urinary Tract Symptoms","enrollment":535},{"nctId":"NCT03229889","phase":"PHASE4","title":"Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2017-06-07","conditions":"Nephrolithiasis","enrollment":220},{"nctId":"NCT05937854","phase":"PHASE2","title":"Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-04-01","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea","enrollment":126},{"nctId":"NCT07391579","phase":"PHASE4","title":"Daily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-12-01","conditions":"Erectile Dysfunctions","enrollment":500},{"nctId":"NCT05051436","phase":"PHASE4","title":"The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics","status":"RECRUITING","sponsor":"Philip Kern","startDate":"2021-12-13","conditions":"Pre-diabetes, Obesity","enrollment":96},{"nctId":"NCT05844462","phase":"PHASE3","title":"Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-02-01","conditions":"Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease","enrollment":200},{"nctId":"NCT03904693","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2019-07-29","conditions":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","enrollment":187},{"nctId":"NCT07245680","phase":"PHASE3","title":"COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-15","conditions":"Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)","enrollment":186},{"nctId":"NCT05206955","phase":"PHASE3","title":"Study of Tadalafil vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-09-16","conditions":"Fontan Palliation","enrollment":80},{"nctId":"NCT07177326","phase":"PHASE3","title":"Combination Therapy of Tadalafil 2.5mg Plus Sildenafil 25mg Versus Tadalafil 5 mg Monotherapy for Treatment of Erectile Dysfunction: A Randomized, Placebo-Controlled Double-Blinded Cross-Over Study","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-01","conditions":"Erectile Dysfunction","enrollment":142},{"nctId":"NCT07172815","phase":"PHASE2","title":"PDE5 Inhibitor for Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Imperial College London","startDate":"2025-09","conditions":"Alzheimer Disease","enrollment":244},{"nctId":"NCT04684589","phase":"PHASE2","title":"Effect of PDE5 Inhibition on Adipose Metabolism in Humans","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-03-16","conditions":"Obesity","enrollment":89},{"nctId":"NCT05030623","phase":"PHASE1, PHASE2","title":"The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-08-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT06290713","phase":"PHASE2","title":"Vasodilator and Exercise Study for DMD (VASO-REx)","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-06-05","conditions":"Duchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy","enrollment":50},{"nctId":"NCT05955001","phase":"PHASE2, PHASE3","title":"Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-04-01","conditions":"Erectile Dysfunction, Lower Urinary Tract Symptoms","enrollment":110},{"nctId":"NCT06962462","phase":"NA","title":"Daily Tadalafil in Diabetic ED Patients","status":"NOT_YET_RECRUITING","sponsor":"South Valley University","startDate":"2025-05-05","conditions":"Erectile Dysfunction Associated With Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT02558231","phase":"PHASE3","title":"The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-05-01","conditions":"Pulmonary Arterial Hypertension","enrollment":247},{"nctId":"NCT06788704","phase":"","title":"Tadalafil Daily Used Post Turp","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2021-05-01","conditions":"Erectile Dysfunction Following Urethral Surgery","enrollment":270},{"nctId":"NCT04483115","phase":"PHASE2","title":"Acute Haemodynamic Study of TPN171H in Patients with Pulmonary Arterial Hypertension","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2020-11-16","conditions":"Pulmonary Arterial Hypertension","enrollment":60},{"nctId":"NCT05173896","phase":"PHASE2","title":"Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christina Kruuse","startDate":"2022-05-31","conditions":"Cerebral Small Vessel Diseases, Stroke, Ischemic","enrollment":100},{"nctId":"NCT05558007","phase":"PHASE2","title":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","status":"RECRUITING","sponsor":"Biozeus Biopharmaceutical S.A.","startDate":"2023-11-22","conditions":"Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer","enrollment":72},{"nctId":"NCT05142254","phase":"PHASE2","title":"A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-01","conditions":"Priapism Due to Sickle Cell Disease","enrollment":64},{"nctId":"NCT06184334","phase":"NA","title":"Management of OAB in Female Patients .","status":"COMPLETED","sponsor":"Elsayed Abdelhalim Elsayed","startDate":"2022-09-14","conditions":"Overactive Bladder","enrollment":300},{"nctId":"NCT06213077","phase":"NA","title":"The Effects of a Nitrate Supplementation on Erectile Function","status":"UNKNOWN","sponsor":"RHA Investments Ltd","startDate":"2023-12-12","conditions":"Erectile Dysfunction","enrollment":20},{"nctId":"NCT04947631","phase":"PHASE3","title":"Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Dongkook Pharmaceutical Co., Ltd.","startDate":"2021-07-27","conditions":"Benign Prostatic Hyperplasia","enrollment":667},{"nctId":"NCT03049540","phase":"PHASE3","title":"Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-10-25","conditions":"Heart Defects, Congenital, Transposition of Great Vessels With Ventricular Inversion","enrollment":100},{"nctId":"NCT05052879","phase":"PHASE3","title":"Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation","status":"NOT_YET_RECRUITING","sponsor":"EMS","startDate":"2024-07","conditions":"Erectile Dysfunction, Premature Ejaculation","enrollment":232},{"nctId":"NCT05789732","phase":"NA","title":"Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones","status":"COMPLETED","sponsor":"Benha University","startDate":"2022-03-30","conditions":"Lower Ureteric Stones, Medical Expulsive Therapy, Tadalafil","enrollment":168},{"nctId":"NCT05787769","phase":"NA","title":"A Randomized Trial to Evaluate Efficacy and Safety of Intracavernosal Injection of Platelet-Rich Plasma Versus Phosphodiesterase Type-5 Inhibitors for Treatment of Erectile Dysfunction.","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-03-01","conditions":"Erectile Dysfunction Following Radiation Therapy, Phosphodiesterase Inhibitor Adverse Reaction, Platelet- Rich Plasma (PRP)","enrollment":96},{"nctId":"NCT05537272","phase":"PHASE4","title":"The Efficacy of Tamsulosin and Tadalafil Compared to Placebo in the Treatment and Prevention of Urinary Disorders After Transperineal Prostate Biopsy","status":"UNKNOWN","sponsor":"University Hospital of Split","startDate":"2022-09-01","conditions":"Lower Urinary Tract Symptoms, Voiding Disorders, Pain","enrollment":120},{"nctId":"NCT02450253","phase":"PHASE2","title":"Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2015-09","conditions":"Dementia, Vascular","enrollment":55},{"nctId":"NCT04500860","phase":"PHASE1","title":"Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2020-12-01","conditions":"Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence","enrollment":90},{"nctId":"NCT02819440","phase":"PHASE2","title":"PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-07","conditions":"Healthy, Obese","enrollment":141},{"nctId":"NCT03641846","phase":"NA","title":"Low-intensity Shockwave Therapy (LiST) for the Treatment of Mild and Mild-to-moderate Vasculogenic Erectile Dysfunction","status":"COMPLETED","sponsor":"Institute for the Study of Urological Diseases, Greece","startDate":"2018-08-28","conditions":"Erectile Dysfunction, Low Intensity Shockwave Therapy","enrollment":50},{"nctId":"NCT05095077","phase":"PHASE1","title":"Effects of Single Dose Tadalafil on Urethral and Anal Closure Function","status":"COMPLETED","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2021-08-01","conditions":"Urinary Incontinence,Stress, Fecal Incontinence","enrollment":24},{"nctId":"NCT05266651","phase":"PHASE2, PHASE3","title":"Efficiency of Tadalafil for Management of Female Sexual Dysfunction","status":"UNKNOWN","sponsor":"Kasr El Aini Hospital","startDate":"2022-03-10","conditions":"Sexual Dysfunction","enrollment":24},{"nctId":"NCT01824290","phase":"PHASE3","title":"A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-02-05","conditions":"Hypertension, Pulmonary","enrollment":35},{"nctId":"NCT03566914","phase":"NA","title":"Tadalafil for Erectile Dysfunction in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2018-06-30","conditions":"Cirrhosis","enrollment":140},{"nctId":"NCT02544880","phase":"PHASE1","title":"PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC","status":"COMPLETED","sponsor":"Donald T. Weed, MD, FACS","startDate":"2016-04-25","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":16},{"nctId":"NCT01970176","phase":"PHASE1, PHASE2","title":"Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-01-09","conditions":"Cardiomyopathy, Renal Impairment","enrollment":20},{"nctId":"NCT02252367","phase":"PHASE4","title":"Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms","status":"COMPLETED","sponsor":"University of Florence","startDate":"2015-12","conditions":"Prostatic Hyperplasia, Lower Urinary Tract Symptoms","enrollment":86},{"nctId":"NCT01862536","phase":"PHASE2","title":"Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2013-10-01","conditions":"Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":44},{"nctId":"NCT02058095","phase":"PHASE1, PHASE2","title":"Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-03","conditions":"Cardiomyopathy, Renal Impairment","enrollment":22},{"nctId":"NCT02595684","phase":"PHASE4","title":"Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2015-08","conditions":"Obesity","enrollment":18},{"nctId":"NCT02194465","phase":"PHASE2","title":"A Study of LY2623091 in Participants With High Blood Pressure","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-08","conditions":"Primary Hypertension","enrollment":304},{"nctId":"NCT04433559","phase":"PHASE3","title":"Study of Pharmacological Treatment in Women With Female Sexual Interest/Arousal Disorder (FSIAD).","status":"UNKNOWN","sponsor":"Lidia Larrañaga","startDate":"2020-08","conditions":"Sexual Dysfunctions, Psychological","enrollment":80},{"nctId":"NCT01697800","phase":"PHASE2","title":"A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT01238224","phase":"PHASE1","title":"Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes","status":"TERMINATED","sponsor":"Vastra Gotaland Region","startDate":"2009-11","conditions":"Type 2 Diabetes","enrollment":22},{"nctId":"NCT02601989","phase":"PHASE2","title":"Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2015-11","conditions":"Diabetes Mellitus, Type 2","enrollment":23},{"nctId":"NCT01865084","phase":"PHASE3","title":"A Study of Tadalafil for Duchenne Muscular Dystrophy","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Muscular Dystrophy, Duchenne","enrollment":331},{"nctId":"NCT01803828","phase":"PHASE4","title":"REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2014-05","conditions":"Diabetic Cardiomyopathy, Diabetes Mellitus Type 2","enrollment":120},{"nctId":"NCT00894413","phase":"PHASE2","title":"A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-05-08","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT01275339","phase":"PHASE4","title":"Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2012-12","conditions":"Aortic Stenosis, LV Remodeling, Hypertrophy","enrollment":10},{"nctId":"NCT01160289","phase":"PHASE2","title":"A Study of LY900010 in Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-10","conditions":"Erectile Dysfunction","enrollment":410},{"nctId":"NCT03905018","phase":"PHASE3","title":"Effect of Tadalafil Administration on Vasodilatation Mediated by Flow in Patients With Obesity Grade I-II","status":"UNKNOWN","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2019-05-01","conditions":"Obesity and Erectile Dysfuntion","enrollment":80},{"nctId":"NCT01272388","phase":"PHASE4","title":"Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-01","conditions":"Aortic Stenosis","enrollment":1},{"nctId":"NCT01661595","phase":"NA","title":"The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2012-11","conditions":"Fatigue","enrollment":30},{"nctId":"NCT01544998","phase":"PHASE1, PHASE2","title":"Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-02","conditions":"Congestive Heart Failure","enrollment":43},{"nctId":"NCT00931528","phase":"PHASE3","title":"Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-11","conditions":"Prostate Cancer, Sexual Dysfunction","enrollment":242},{"nctId":"NCT02999906","phase":"PHASE3","title":"Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension","status":"WITHDRAWN","sponsor":"United Therapeutics","startDate":"2017-10","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT01960153","phase":"PHASE3","title":"Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2013-10","conditions":"Heart Failure, Pulmonary Hypertension","enrollment":""},{"nctId":"NCT02801032","phase":"PHASE2","title":"Effect of Tadalafil on Cerebral Large Arteries in Stroke","status":"COMPLETED","sponsor":"Christina Kruuse","startDate":"2016-11-29","conditions":"Stroke, Lacunar, Cerebral Small Vessel Diseases","enrollment":20},{"nctId":"NCT02431754","phase":"PHASE4","title":"A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-04","conditions":"Benign Prostatic Hyperplasia","enrollment":171},{"nctId":"NCT01937871","phase":"PHASE3","title":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-09","conditions":"Benign Prostate Hyperplasia, Erectile Dysfunction","enrollment":909},{"nctId":"NCT01291069","phase":"PHASE1","title":"Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients","status":"COMPLETED","sponsor":"University of Utah","startDate":"2011-09","conditions":"Single Ventricle","enrollment":20},{"nctId":"NCT01444651","phase":"PHASE3","title":"A Trial of Tadalafil and Glycemic Traits","status":"COMPLETED","sponsor":"Thomas J. Wang, MD","startDate":"2011-08","conditions":"Cardiovascular Disease, Insulin Resistance, Glucose Intolerance","enrollment":73},{"nctId":"NCT02554045","phase":"PHASE4","title":"Daily Tadalafil on Body Fat and Lean Mass","status":"COMPLETED","sponsor":"University of Roma La Sapienza","startDate":"2015-01","conditions":"Obesity, Sexual Dysfunction","enrollment":20},{"nctId":"NCT00538564","phase":"PHASE2","title":"Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2006-11","conditions":"Sickle Cell Anemia, Priapism","enrollment":""},{"nctId":"NCT02862483","phase":"PHASE3","title":"The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2016-03","conditions":"Benign Prostatic Hyperplasia, Erectile Dysfunction","enrollment":330},{"nctId":"NCT00843635","phase":"NA","title":"Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx","status":"COMPLETED","sponsor":"Donald T. Weed","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT00215631","phase":"PHASE3","title":"Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer?","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2005-10","conditions":"Prostate Cancer, Erectile Dysfunction","enrollment":100},{"nctId":"NCT01067391","phase":"PHASE4","title":"Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2009-10","conditions":"Hypotension, Spinal Cord Injury","enrollment":20},{"nctId":"NCT01910389","phase":"PHASE3","title":"Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure","status":"TERMINATED","sponsor":"Carelon Research","startDate":"2013-11","conditions":"Heart Failure, Pulmonary Hypertension","enrollment":23},{"nctId":"NCT01553981","phase":"PHASE3","title":"A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2012-03","conditions":"Lung Diseases, Interstitial","enrollment":40},{"nctId":"NCT00750308","phase":"NA","title":"Renin Angiotensin Aldosterone System (RAAS) and Fibrinolysis in Humans: ACEi and PE5i","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2006-12","conditions":"Metabolic Syndrome","enrollment":27},{"nctId":"NCT00822354","phase":"NA","title":"Tadalafil for the Treatment of Raynaud's","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Raynaud","enrollment":10},{"nctId":"NCT01423370","phase":"PHASE2","title":"Safety and Efficacy of YHD1023 in Erectile Dysfunction","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2011-11","conditions":"Erectile Dysfunction","enrollment":104},{"nctId":"NCT01026818","phase":"PHASE4","title":"A Study of Tadalafil After Radical Prostatectomy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-11","conditions":"Erectile Dysfunction","enrollment":583},{"nctId":"NCT01460342","phase":"PHASE3","title":"Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Benign Prostatic Hyperplasia","enrollment":610},{"nctId":"NCT01070511","phase":"PHASE4","title":"Tadalafil in Becker Muscular Dystrophy","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2010-01","conditions":"Becker Muscular Dystrophy","enrollment":48},{"nctId":"NCT01302444","phase":"PHASE4","title":"Treprostinil Combined With Tadalafil for Pulmonary Hypertension","status":"TERMINATED","sponsor":"Rhode Island Hospital","startDate":"2011-03","conditions":"Pulmonary Arterial Hypertension","enrollment":1},{"nctId":"NCT01152190","phase":"PHASE3","title":"A Study in Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-09","conditions":"Benign Prostatic Hyperplasia","enrollment":97},{"nctId":"NCT00626665","phase":"PHASE3","title":"Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2007-12","conditions":"Raynaud Disease","enrollment":25},{"nctId":"NCT01139762","phase":"PHASE3","title":"A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-09","conditions":"Benign Prostatic Hyperplasia, Enlarged Prostate","enrollment":696},{"nctId":"NCT01063855","phase":"PHASE3","title":"Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-04","conditions":"Erectile Dysfunction, Sexual Dysfunction","enrollment":495},{"nctId":"NCT01130532","phase":"PHASE4","title":"A Study in Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-08","conditions":"Erectile Dysfunction","enrollment":623},{"nctId":"NCT01197469","phase":"PHASE2","title":"Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":120},{"nctId":"NCT00617305","phase":"PHASE4","title":"Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-04","conditions":"Pulmonary Arterial Hypertension","enrollment":38},{"nctId":"NCT00970632","phase":"PHASE3","title":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":511},{"nctId":"NCT00855582","phase":"PHASE3","title":"A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Erectile Dysfunction, Benign Prostatic Hyperplasia","enrollment":606},{"nctId":"NCT00861757","phase":"PHASE3","title":"Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Benign Prostatic Hyperplasia","enrollment":612},{"nctId":"NCT00783094","phase":"PHASE2","title":"Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-11","conditions":"Benign Prostatic Hyperplasia","enrollment":422},{"nctId":"NCT00836693","phase":"PHASE3","title":"Effect of Tadalafil Once a Day in Men With Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-01","conditions":"Erectile Dysfunction","enrollment":217},{"nctId":"NCT00540124","phase":"PHASE2","title":"Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Benign Prostatic Hyperplasia","enrollment":151},{"nctId":"NCT00827242","phase":"PHASE3","title":"Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-01","conditions":"Benign Prostatic Hyperplasia","enrollment":325},{"nctId":"NCT00848081","phase":"PHASE3","title":"A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-03","conditions":"Benign Prostatic Hyperplasia","enrollment":318},{"nctId":"NCT01200732","phase":"PHASE2","title":"Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome","status":"COMPLETED","sponsor":"Govind Ballabh Pant Hospital","startDate":"2008-02","conditions":"Eisenmenger Syndrome","enrollment":28},{"nctId":"NCT00833638","phase":"PHASE4","title":"A Study in Erectile Dysfunction","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-02","conditions":"Erectile Dysfunction","enrollment":372},{"nctId":"NCT01117298","phase":"PHASE3","title":"A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma","status":"COMPLETED","sponsor":"Sanjay Gandhi Postgraduate Institute of Medical Sciences","startDate":"2009-11","conditions":"Raynaud's Phenomenon, Digital Ulcers, Scleroderma","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cialis"],"phase":"phase_3","status":"active","brandName":"placebo (tadalafil)","genericName":"placebo (tadalafil)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tadalafil, also known as a placebo, has been studied in clinical trials for various conditions, including Benign Prostatic Hyperplasia (BPH) and urinary incontinence. The exact mechanism of tadalafil is not specified in the provided facts, but it is listed as an intervention in clinical trials for these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}